A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer

SIMPLE SUMMARY: HER2+ metastatic breast cancer (MBC) is a highly prevalent type of breast cancer owing to its resistance to conventional anti-HER2 drugs. Therefore, novel agents that can arrest tumor progression and enhance the overall survival rates of HER2+ breast cancer patients, which would repr...

Descripción completa

Detalles Bibliográficos
Autor principal: Alasmari, Moudi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817862/
https://www.ncbi.nlm.nih.gov/pubmed/36612034
http://dx.doi.org/10.3390/cancers15010038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817862/
https://www.ncbi.nlm.nih.gov/pubmed/36612034
http://dx.doi.org/10.3390/cancers15010038

Ejemplares similares